Heart failure & cardiomyopathies
DAPAgliflozin for renal protection in heart transplant recipients. Rationale and design of the randomized controlled DAPARHT trial
Study context
- Population
- Adults heart transplanted at least one year prior to randomization; exclusion criteria include estimated glomerular filtration rate (eGFR) <25 mL/min/1.73 m², diabetes type I, and contraindication to study medicationplanned randomization, as of December 18, 2024, 300 patients were enrolled
- Participants
- Four hundred and thirty participants
- Planned comparison
- dapagliflozin 10 mg o.d. or placebo
- Primary endpoint
- chronic slope of the eGFR
- Follow-up
- From two weeks to 12 months after starting randomized treatment
Methodological detailsrationale and design, 1:1 randomization, 12 months blinded treatment followed by 24-months open-label treatment
- Rationale and design
- 1:1 randomization
- 12 months blinded treatment followed by 24-months open-label treatment
No results yet. This paper sets out the design of a trial; its results are to come.
Baseline
Enrolment status · As of December 18, 2024
- Enrolment began
- June 2022
- Patients enrolled
- 300
- Estimated last patient visit
- September, 2028
Baseline kidney function (enrolled patients)
- Mean baseline creatinine
- 104 ± 28 µmol/L
- eGFR
- 66 ± 22 mL/min/1.73 m²
Original publication
DAPAgliflozin for renal protection in heart transplant recipients. Rationale and design of the randomized controlled DAPARHT trial. Am Heart J. Published 19 August 2025. doi:10.
Summarised from the published abstract; every number is checked against it